The tyrosine kinase inhibitor imatinib has been shown to reduce airway hyper-responsiveness in patients with poorly controlled severe asthma. The proof-of-principle study, published in NEJM and presented at the American Thoracic Society conference in Washington this week, also found imatinib reduced mast cell counts and a marker of mast cell activation. While the US study ...
Cancer drug shows early promise for severe asthma
By Mardi Chapman
25 May 2017